

Guideline Recommendations

Guidelines	2017 ACC/AHA/HFSA Focused Update of the U.S. Guideline for Management of HF	2016 ESC Guidelines for Diagnosis and Treatment of Acute and Chronic HF
Target HF population	NYHA functional class II and III	Symptomatic HFrEF
Recommendations	IV iron replacement might be reasonable to improve functional status and QOL	IV FCM should be considered in order to alleviate HF symptoms and improve exercise capacity and QOL
Class of recommendation	IIb	IIa
Level of recommendation	B	A

2017 AHA/ACC/HFSA Focused Update -Guidelines in Management of HF

III. No Benefit	B-R	In patients with HF and anemia, erythropoietin-stimulating agents should not be used to improve morbidity and mortality
-----------------	-----	---


2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment

Guidance on appropriate Iron deficiency management option in patients with HFrEF

Comorbidity	Association With Heart Failure Outcomes	Clinical Trial Evidence for Modulating Comorbidity	Suggested Action
Iron deficiency	Strong	Intermediate	Consider intravenous iron replacement for symptom improvement

Algorithm for screening/diagnosis and treatment/follow-up of iron deficiency in patients with chronic heart failure.


Chronic HFrEF (NYHA II-IV)



Consider single doses of ferric carboxymaltose (**500-100 mg iron**) to correct iron deficiency*

Calculate total iron need using the table:

Hemoglobin		Patient body weight		
g/dL	mmol/L	<35 kg	35 kg to <70 kg	≥70 kg
<10	<6.2	500 mg	1500 mg	2000 mg
10 to <14	6.2 to <8.7	500 mg	1000 mg	1500 mg
≥14 to 15	≥8.7 to 9.3	500 mg	500 mg	500 mg



Hb = hemoglobin, HF = heart failure, HFrEF = heart failure with reduced ejection fraction, FCM = ferric carboxymaltose, NYHA = New York Heart Association Functional Classification, QOL = quality of life, TSAT = transferrin saturation

REFERENCES:

- Yancy, Clyde W., et al. "2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America." *Journal of the American College of Cardiology* 70.6 (2017): 776-803.
- Ponikowski, Piotr, et al. "2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure." *Kardiologia Polska* (Polish Heart Journal) 74.10 (2016): 1037-1147.
- McDonagh, Theresa, et al. "Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice." *European journal of heart failure* 20.12 (2018): 1664-1672.
- Maddox, Thomas M., et al. "2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee." *Journal of the American College of Cardiology* 77.6 (2021): 772-810.